Michael Kyba, PhD, Darko Bosnakovski, DVM, PhD, and their team discovered a way to deactivate DUX4 and take away the toxic effects in cells, as well as in a mouse model for FSHD.
New research has shown that survival outcomes for pediatric cancer patients after an organ transplant were very promising and appeared similar to general outcomes. This study demonstrated it is a viable option for physicians and insurance companies to consider when making a decision.
On July 31, Cardio Palooza broke records and brought in more than 200 scholars from throughout the University, including 84 poster presenters and 36 faculty judges.
The National Academy of Medicine has identified a CMV vaccine as being the highest public health priority for any new vaccine.
New research from the University of Minnesota Medical School has discovered critical mutations in molecules implicated in obesity, which may help inform the development of new anti-obesity therapies.
The University of Minnesota Medical School is at the forefront of developing a cell-based therapy for Duchenne muscular dystrophy (DMD).
Dr. Bernadette Gillick has received an R21 Exploratory/Developmental grant from the National Institutes of Health/Eunice Kennedy Shriver National Institute of Child Health & Human Development.
Cytomegalovirus or CMV is a common virus that infects people of all ages. Over half of adults by age 40 have been infected with CMV.
August is National Immunization Awareness Month, which is held every year to highlight the importance of vaccination for people of all ages.
The five year project aims to study an enzyme-driven mutation process in breast cancer cells.